Scientific and Medical Equipment House (4014.SR) — Cash flow
Operating, investing, and financing cash flow for Scientific and Medical Equipment House — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 28↓27.3% | 39↓26.2% | 53↑201.4% | 18↓77.3% | 78 | |
| Depreciation & Amortization | 17↓12.6% | 20↓12.2% | 23↑67.7% | 14↑5.4% | 13 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -74↓137.0% | 201↑177.6% | -259↓997.1% | 29↑115.3% | -188 | |
| Accounts Receivable | -101↓146.9% | 216↑196.6% | -223↓397.4% | 75↑133.8% | -222 | |
| Inventory | 35↑999.2% | 3↑130.7% | -10↓126.3% | -5↑62.3% | -12 | |
| Accounts Payable | -8↓226.6% | 7↑134.8% | -19↓324.9% | 8↑21.3% | 7 | |
| Other Working Capital | 0.32↑101.3% | -25↓287.2% | -6↑87.3% | -50↓228.0% | 39 | |
| Other Non-Cash Items | 23↓11.5% | 26↓39.7% | 43↓33.3% | 64↑382.6% | 13 | |
| Net Cash from Operating Activities | -6↓102.0% | 286↑303.2% | -141↓213.4% | 124↑246.4% | -85 | |
| Operating Cash Flow | -6↓102.0% | 286↑303.2% | -141↓213.4% | 124↑246.4% | -85 | |
| Investing Activities | ||||||
| Investment in Property, Plant & Equipment | -8 | 0.00↑100.0% | -15↑16.5% | -18↓139.2% | -7 | |
| Capital Expenditure | -7↓59.9% | -4↑70.3% | -15↑16.5% | -18↓139.2% | -7 | |
| Acquisitions | 3 | 0.00 | 0.00↓100.0% | 0.17↑123.2% | -0.72 | |
| Purchases of Investments | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.96 | |
| Sales & Maturities of Investments | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 12 | |
| Other Investing Activities | -2↑10.9% | -3↓5052.1% | -0.05↓173.0% | 0.07↓65.0% | 0.20 | |
| Net Cash from Investing Activities | -7↓175.7% | -3↑82.2% | -15↑15.1% | -18↓476.6% | 5 | |
| Financing Activities | ||||||
| Net Debt Issuance | -16↑88.9% | -148↓196.3% | 154↑326.5% | -68 | 0.00 | |
| Long-Term Net Debt Issuance | -2↓24.0% | -1↓233.3% | -0.38↓117.8% | 2 | 0.00 | |
| Short-Term Net Debt Issuance | -15↑89.9% | -147↓195.3% | 154↑320.2% | -70 | 0.00 | |
| Net Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | -30↑0.0% | -30 | 0.00↑100.0% | -20↑33.3% | -30 | |
| Common Dividends Paid | -30↑0.0% | -30 | 0.00↑100.0% | -20↑33.3% | -30 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -8↑75.8% | -34↑6.8% | -36↓292.5% | -9↓113.6% | 68 | |
| Net Cash from Financing Activities | -55↑74.2% | -212↓279.7% | 118↑221.3% | -97↓364.6% | 37 | |
| Cash Reconciliation | ||||||
| Effect of Foreign Exchange | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | |
| Net Change in Cash | -68↓195.0% | 71↑289.1% | -38↓507.2% | 9↑121.3% | -43 | |
| Cash at Beginning of Period | 88↑419.6% | 17↓68.9% | 55↑20.4% | 45↓48.9% | 89 | |
| Cash at End of Period | 20↓76.8% | 88↑419.6% | 17↓68.9% | 55↑20.4% | 45 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | -13↓104.5% | 286↑283.8% | -156↓246.4% | 106↑215.2% | -92 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.